Background {#Sec1}
==========

Over 20 years ago, Woolf \[[@CR1]--[@CR3]\] described clinical practice guidelines (CPGs) as 'the new reality for medicine'. Research continues into how best to present this 'new reality' to end users in a way that will improve evidence uptake. Whilst there is no one internationally-agreed standard for developing CPGs \[[@CR4]--[@CR6]\], there is a general expectation that CPG recommendations should be transparently based on current best evidence \[[@CR7]--[@CR11]\].

End-users of CPGs are those who put CPG recommendations into operation, such as service managers and healthcare workers 'at the coal face'. These people are rarely engaged in CPG writing \[[@CR12]\], however they are usually well aware of the barriers to evidence-uptake \[[@CR13]--[@CR16]\]. These are consistently reported as lack of time, money, and knowledge \[[@CR3], [@CR13]--[@CR16]\]. Thus when end-users choose a CPG, they need to be assured that it is of the best possible quality, and that it will efficiently assist them to provide quality care. Service managers and clinicians are busy people, and therefore to assist them in efficiently identifying and using quality CPGs, they require a time-efficient critical appraisal instrument that is comprehensive, simple, robust and efficient.

An Australian team at the International Centre for Allied Health Evidence (iCAHE), University of South Australia, developed and tested a 14 question binary-scored (yes = 1, no = 0) CPG appraisal instrument, designed specifically for busy end-users \[[@CR17]\]. The iCAHE instrument was developed in partnership with service managers, policy-makers and clinicians, and incorporated their perceptions of important elements of CPG quality relevant to their settings. The iCAHE instrument contains 14 questions and provides one overall score (total out of 14). This scoring approach assumes equal weighting for each question, reflecting the views held by the end-users who assisted in its development.

The psychometric properties of the iCAHE instrument were established by comparison with AGREE II (Appraisal of Guideline Research and Evaluation), a complex CPG critical appraisal instrument \[[@CR7], [@CR18]--[@CR20]\]. AGREE II is well-known internationally, and is recommended for assessing CPG quality by the South African Medical Journal \[[@CR8], [@CR9]\]. AGREE II has 23 statements grouped into six domains of Scope and Purpose; Stakeholder Involvement; Rigour of Development; Clarity of Presentation; Applicability; and Editorial Independence. Each statement is scored using a 1--7 scale, with 1 being no agreement and 7 being total agreement. The six domains in AGREE II are intended to be reported separately, and the scoring rubric is not designed to provide an overall quality score \[[@CR18], [@CR19]\].

The iCAHE and AGREE II instruments share four domains (Scope and Purpose, Stakeholder involvement, Underlying evidence/Rigour, Clarity). The iCAHE instrument also includes three domains not in AGREE II (currency, a summary of findings, and availability), whilst AGREE II includes two domains not in the iCAHE instrument (Applicability, and Independence) (see Table [1](#Tab1){ref-type="table"}). The scores and utility of the iCAHE and AGREE II instruments were compared using six CPGs for mild traumatic brain injury \[[@CR17]\]. Overall, the iCAHE and AGREE II scores correlated moderately well (Pearson *r* = 89 %). Depending on the complexity of CPG layout, the iCAHE instrument took between 5 and 10 min per-CPG to apply, whilst the AGREE II instrument scoring per-CPG per-tester took up to an hour.Table 1iCAHE questions mapped against AGREE II domains and their statementsiCAHEAGREE IIAGREE II domain 1: scope and purposeQ13 Are the purpose and target users of the guideline stated?Q1. The overall objectives of the guideline are specifically describedQ2. The health questions covered by the guideline are specifically describedQ3. The population to whom the guideline is meant to apply is specifically describedAGREE II domain 2: stakeholder involvementQ6. The target users are clearly definedQ11. Are the developers clearly stated?Q4. The guideline development group includes individuals from all relevant professional groupsQ12. Does the qualifications and expertise of the guideline developers link with the purpose of the guideline and its end users?Q5. The views and preferences of the target population have been soughtAGREE II domain 3: rigour of developmentQ7. Does the guideline provide an outline of the strategy used to find underlying evidence?Q7. Systematic methods were used to search for the evidenceQ8. Does the guideline use a hierarchy to rank the quality of the underlying evidence?Q8. The criteria for selecting the evidence are clearly describedQ9. Does the guideline appraise the quality of the evidence which underpins its recommendations?Q9. The strengths and limitations of the body of evidence are clearly describedQ10. Does the guideline link the hierarchy and quality of underlying evidence to each recommendation?Q10. The methods for formulating the recommendations are clearly describedQ11. The health benefits, side effects and risks have been considered in formulating the recommendationsQ12. There is an explicit link between the recommendations and the supporting evidenceQ13. The guideline has been eternally reviewed by experts prior to its publicationQ14. A procedure for updating the guideline is providediCAHE instrument domain: currencyQ4. Is there a date of completion available?Q5. Does the guideline provide an anticipated review date?Q6. Does the guideline provide dates for when literature was included?AGREE II domain 4: clarity of presentationQ14. Is the guideline readable and easy to navigate?Q15. The recommendations are specific and unambiguousQ16. The different options for management of the condition or health issues are clearly presentedQ17. Key recommendations are easily identifiableAGREE II domain 5: applicabilityQ18. The guideline describes facilitators and barriers to its applicationQ19. The guideline provides advice and/or tools on how the recommendations can be put into practiceQ20. The potential resources implications of applying the recommendations have been consideredQ21. The guideline presents monitoring and/or auditing criteriaAGREE II domain 6: editorial independenceQ22. The views of the funding body have not influenced the content of the guidelineQ23. Competing interests of guideline development group members have been recorded and addressediCAHE instrument domain: availabilityQ1. Is the guideline readily available in full text?Q2. Does the guideline provide a complete reference list?iCAHE instrument domain: summaryQ3. Does the guideline provide a summary of its recommendations?Adapted from Grimmer et al. \[[@CR17]\]

The South African Guidelines Excellence (SAGE) is a project which aims to improve the quality of South African primary health care (PHC) CPGs. It is pursuing several research activities, namely identifying, and speaking with, key individuals and groups involved in PHC CPG writing and use in South Africa; determining the quality of current South African PHC CPGs and identifying ways to improve their quality; and building capacity in best practice CPG writing, implementation and evaluation in South African academics, clinicians and policy-makers \[[@CR21]\]. The SAGE team recently reported on the quality of 16 purposively-sampled South African CPGs for priority PHC conditions, using AGREE II \[[@CR22]\]. These CPGs comprised the most recent versions of seven disease-specific and four integrated multi-disease South African PHC CPGs (see Table [2](#Tab2){ref-type="table"}, reproduced from Machingaidze et al. \[[@CR22]\]). The dates of CPG publication ranged from 2002 to 2014. Overall, the quality domains of Rigour of Development, and Editorial Independence had the poorest scores, whilst Scope and Purpose, and Clarity of Presentation generally scored the best. The time taken to score each selected CPGs with AGREE II ranged between 45 and 60 min, depending on CPG layout, comprehensiveness and complexity.Table 2South African CPGs included in this analysis (reproduced from Machingaidze et al. \[[@CR22]\])NameShort namePublication yearDeveloper*Disease specific guidelines*Clinical guidelines for the management of HIV and AIDS in adults and adolescentsAdult HIV2010National Department of HealthGuidelines for the management of HIV in childrenChild HIV2010National Department of HealthClinical guidelines: PMTCT (prevention of mother-to-child transmission)PMTCT2010National Department of HealthNational tuberculosis management guidelinesAdult TB2014National Department of HealthGuidelines for the management of tuberculosis in childrenChild TB2013National Department of HealthMalaria prevention guidelinesMalaria prevention2011National Department of HealthMalaria treatment guidelinesMalaria treatment2010National Department of Health*Combination guidelines*Standard treatment guidelines and essential medicines list for South AfricaEDL2008National Department of HealthIntegrated management of childhood illnessesIMCI2002National Department of HealthGuidelines for maternity care in South AfricaMaternal2007National Department of HealthPrimary care 101PC1012013UCT Lung Institute/National Department of Health*Guidelines by professional societies*Guideline for the management of acute asthma in adults: 2013 updateAdult asthma2013South African Thoracic SocietyGuideline for the management of acute asthma in children: 2013 updateChild asthma2013South African Thoracic SocietyGuideline for the management of chronic obstructive pulmonary disease---2011 updateCOPD2011South African Thoracic SocietySouth African hypertension guideline 2011Hypertension2011Southern African Hypertension SocietyThe 2012 SEMDSA guideline for the management of type 2 diabetes (Revised)Type II diabetes2012Society for endocrinology, metabolism and diabetes of South Africa

AGREE II was developed for, and has been largely used by, researchers and CPG developers, thus its use may present challenges for time-constrained end-users who have to assess CPG quality by themselves. The iCAHE instrument could be a viable alternative to AGREE II when a rapid overview of CPG quality is required. This paper describes how the iCAHE instrument compares to the AGREE II instrument on a larger set of heterogeneous CPGs.

Methods {#Sec2}
=======

Data set {#Sec3}
--------

The same 16 purposively-selected South African PHC CPGs reported by Machingaidze et al. \[[@CR22]\] were assessed using the iCAHE instrument, and the scores from the two instruments were compared.

Scoring {#Sec4}
-------

The iCAHE instrument was applied by one independent experienced tester whose level of experience was similar to that of the testers who applied the AGREE II instrument \[[@CR22]\].

Data management {#Sec5}
---------------

To facilitate comparison between instrument scores for each CPG, a percent of possible total (overall) score was calculated for the iCAHE instrument and also from the AGREE II instrument. This approach was previously used when initially validating the iCAHE instrument against AGREE II \[[@CR17]\], even though a total AGREE II score is not calculated from the AGREE II domain rubric \[[@CR18], [@CR19]\]. To calculate one percent total score, the individual item responses for all AGREE II statements were applied to the scoring rubric, using a minimum possible score of 23 (calculated as 23 items\*1), and a maximum possible score of 171, calculated as 23 items\*7. This score was then reported as a percentage of the possible total.

Analysis {#Sec6}
--------

Correlation between instrument scores was reported as Pearson correlation coefficients *(*Pearson *r)*. Significance of instrument score differences was determined using *p* values from single factor analysis of variance (ANOVA) models, and intraclass correlation coefficients (ICC~(2,1)~) were calculated from the mean square outputs of these ANOVA models. The ICC~(2,1)~ calculation assumed that the testers were similar to those who might use the instruments in other situations. CPGs with instrument score differences of \>10 % (where positive differences favoured the iCAHE instrument) were identified. The two datasets were:The % total iCAHE scores and the % total AGREE II scores for each CPG, using all items in each instrument (23 AGREE II statements, 14 iCAHE questions).The % total scores for only the items in the instruments' common domains (Scope and Purpose, Stakeholder involvement, Rigour of development, Clarity of Presentation). This involved eight iCAHE questions and 17 AGREE II statements. The same process of calculating total AGREE II scores was used as described in the *Data management* paragraph, however the denominators were 8 (8\*1) for iCAHE and 119 (17 items\*7) for AGREE II.

The time spent critically appraising the iCAHE instrument was recorded for each CPG, and compared with the time reported by Machingaidze et al. \[[@CR22]\].

Results {#Sec7}
=======

Overall CPG quality {#Sec8}
-------------------

Irrespective of whether the iCAHE or AGREE II instrument was used, or the number of questions/statements compared, the overall quality of reporting in the South African PC CPGs was generally poor (See Table [3](#Tab3){ref-type="table"}; Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}).Table 3CPG scores for iCAHE questions mapped against AGREE II domainsDomainsiCAHE questionsDisease specific guidelinesCombination guidelinesGuidelines by professional societiesAdult HIVChild HIVPMTCTAdult TBChild TBMalaria preventionMalaria treatmentEDLIMCIMaternalPC101Adult asthmaChild asthmaCOPDHypertensionType II diabetesAGREE II domain 1: scope and purposeQ131110111111100111AGREE II domain 2: stakeholder involvementQ110000011101111111Q120000011001011111AGREE II domain 3: rigour of developmentQ70000000000001000Q80000000000011000Q90000000000000000Q100000000000000000New iCAHE domain: currencyQ41111111111111011Q50000000000000000Q60000000000001000AGREE II domain 4: clarity of presentationQ141110111111111111New iCAHE domain: summaryQ31111111010111111New iCAHE domain: availabilityQ11111111111111111Q20011011000011111Guideline % score^a^36364329365757363643435771505757*1* Yes (criterion was addressed), *0* No (criterion not addressed)^a^Domain percentage scores are calculated as the total number of yes questions divided by the total number of possible questions and converted into a percentageFig. 1Analysis 1 findings: comparison of % of total scores per CPG, including all questions (iCAHE instrument) and statements (AGREE II)Fig. 2Analysis 2 findings: comparison of % of total scores per CPG for the common domains only

Table [4](#Tab4){ref-type="table"} reports the findings from analyses 1 and 2. Comparing analysis 1 with 2, there was an improved correlation between instrument scores for analysis 2, as well as a stronger ICC~(2,1)~ score (with a lower, but not significant, p value). There were no significant percentage of score differences overall, from either analysis 1 or 2. However from analysis 1, the large score differences all favoured the iCAHE instrument (see Fig. [1](#Fig1){ref-type="fig"}), whilst from analysis 2, the large score differences mostly favoured the AGREE II instrument (see Fig. [2](#Fig2){ref-type="fig"}).Table 4*Pearson r* correlation coefficients, ICC~(2,1)~ values for agreement and CPGs with disagreements \>10 %, listed by order of size of disagreement for analyses 1 and 2Pearson r correlation coefficientAgreement expressed as ICC~(2,1)~ valuesCPGs with disagreements \> 10 % between instrumentsSize of disagreement (-ve values in favour of AGREE II) (%)Analysis 1: using all statements in both instruments*0.39ICC* = *0.06 (p* = *0.39)(6 of 16)*Child asthma34.8 Adult asthma23.3 Malaria treatment22.7 Malaria prevention18.9 COPD17.4 Hypertension17.1 Analysis 2: using only the statements in the common domains between the instruments*0.61ICC* = *0.49 (p* = *0.07)(7 of 16)*Child asthma17.1 Adult asthma10.9 Adult HIV−14.5Child HIV−15.3PMTCT−15.3PC101−24.7Adult TB−29.0

The time to use the iCAHE instrument was 3--5 min per CPG. This mirrored earlier findings on the utility of the iCAHE instrument \[[@CR17]\].

Discussion {#Sec9}
==========

This study compare findings from a complex CPG critical appraisal instrument (AGREE II) with a rapid appraisal instrument (iCAHE), on a sizeable sample of heterogeneous country-specific PHC CPGs. Scoring CPG quality is an essential element of evidence implementation \[[@CR10], [@CR11], [@CR13]--[@CR16]\]. Unless end-users have confidence in the quality of the evidence underpinning CPG recommendations, they are unlikely to adopt them. CPGs offer ready access to a 'one-stop-shop' for current best evidence-summaries \[[@CR1]--[@CR3]\]. Irrespective of which critical appraisal instrument was used (rapid or complex), we identified consistent concerns relating to the quality of the selected South African PHC CPGs, particularly in Rigour of Development. This is a similar finding to other studies evaluating South African CPG quality \[[@CR8], [@CR9]\].

Analysis 1, which compared the per-CPG total scores derived from the 23 AGREE statements, and the 14 iCAHE questions, demonstrated the modesty of both correlation and agreement. This was attributed to the variability in number and intent, in the two instruments' items. For instance, whilst there were four common domains between instruments, the iCAHE questions included additional domains of Currency, Availability, and Summary, whilst the AGREE II instrument included additional domains of Applicability and Editorial Independence. Comparing differences in total scores, all six CPGs with large percent differences (\>10 %) favoured the iCAHE instrument.

Analysis 2, which compared data from just the four shared domains in the iCAHE and AGREE II instruments, showed improved correlation and agreement, but identified different CPGs with large score differences (with only two of the seven highlighted CPGs favouring the iCAHE instrument). This suggests that the between-instrument differences in the number of statements/questions in the common domains possibly influenced the scoring (8 iCAHE questions in four domains, 17 AGREE II statements in the same four domains). This potentially weighted the overall score in favour of AGREE II.

The shorter time taken to score CPG quality using iCAHE instrument compared with AGREE II reflects the smaller number of items, as well as the utility of the binary-scored iCAHE instrument, where no subjectivity in interpretation is required. In comparison, Machingaidze et al. \[[@CR22]\] reported that the AGREE II scores took as much as 10 times longer to compile per CPG, as its use required personal judgement identify a score from 1 to 7 for each statement, and then the application of a scoring rubric per domain. As previously reported \[[@CR17]\], this potentially introduces uncertainty in critical appraisal.

Conclusions {#Sec10}
===========

Both appraisal instruments provide standard valid and reliable frameworks for assessment of CPG quality, albeit oriented for different end users. Thus either instrument could be used with confidence to assess the quality of a CPG, and the choice of instrument would depend on the purpose of appraisal, available time and whether additional personnel were available to apply the AGREE II scoring requirements. Having an alternative (rapid) critical appraisal tool will potentially encourage busy end-users who may not currently use complex tools such as AGREE II, to identify good quality CPGs to inform practice and policy decisions.
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